EP Patent

EP2810644A1 — Oral formulation for the treatment of cardiovascular diseases

Assigned to Ferrer Internacional SA · Expires 2014-12-10 · 11y expired

What this patent protects

The present invention relates to a pharmaceutical composition which includes a HMG-CoA reductase inhibitor, in particular, a statin and acetylsalicylic acid in a manner to minimize interaction of acetylsalicylic acid with the statin, for use in the prevention or treatment of card…

USPTO Abstract

The present invention relates to a pharmaceutical composition which includes a HMG-CoA reductase inhibitor, in particular, a statin and acetylsalicylic acid in a manner to minimize interaction of acetylsalicylic acid with the statin, for use in the prevention or treatment of cardiovascular diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP2810644A1
Jurisdiction
EP
Classification
—
Expires
2014-12-10
Drug substance claim
No
Drug product claim
No
Assignee
Ferrer Internacional SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.